Currently out of the existing stock ratings of Adam Maeder, 310 are a BUY (74.7%), 95 are a HOLD (22.89%), 10 are a SELL (2.41%).

Adam Maeder

Work Performance Price Targets & Ratings Chart

Analyst Adam Maeder, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 61.54% that have a potential upside of 39.58% achieved within 232 days.

Adam Maeder’s has documented 813 price targets and ratings displayed on 31 stocks. The coverage is on Healthcare, Consumer Cyclical, Financial Services, Technology sectors.

Most recent stock forecast was given on LIVN, LivaNova PLC at 02-Sep-2026.

Wall Street Analyst Adam Maeder

Analyst best performing recommendations are on RBOT (VICARIOUS SURGICAL).
The best stock recommendation documented was for RBOT (VICARIOUS SURGICAL) at 11/13/2024. The price target of $10.5 was fulfilled within 1 day with a profit of $1.35 (14.75%) receiving and performance score of 147.54.

Average potential price target upside

of $55.58 (61.47%) on GKOS (GLAUKOS CORP).
of $42.16 (16.15%) on ISRG (INTUITIVE SURGICAL).
of $38.48 (26.66%) on SWAV (SHOCKWAVE MEDICAL).

APEN Apollo Endosurgery AXNX Axonics Modulation Technologies EW Edwards Lifesciences Corp INSP Inspire Medical Systems ISRG Intuitive Surgical LIVN LivaNova PLC NVRO Nevro Corp SILK Silk Road Medical STIM Neuronetics STXS Stereotaxis SWAV Shockwave Medical TCMD Tactile Systems Technology XENT Intersect ENT NYXH Nyxoah ZYXI Zynex RBOT Vicarious Surgical NARI Inari Medical NSPR InspireMD ABT Abbott Laboratories M Macy’s RMD ResMed RXST Rxsight TMDI Titan Medical SGHT Sight Sciences AP Ampco-Pittsburgh AX Axos Financial SI Silvergate Capital STX Seagate Technology PLC SW Smurfit WestRock plc GKOS Glaukos Corp STAA STAAR Surgical Company

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Joshua Jennings (TD COWEN)

Buy Since 15-Dec-2021

$10

$13

3 years 9 months 1 days ago
(23-Jan-2023)

1/2 (50%)

$0.16 (1.63%)

Please subscribe to see extended stock data

Mathew Blackman (TD COWEN)

Buy Since 10-Dec-2021

$10

3 years 9 months 20 days ago
(04-Jan-2023)

6/7 (85.71%)

$0.12 (1.21%)

171

Please subscribe to see extended stock data

Frank Takkinen (LAKE STREET)

Buy Since 17-May-2021

$10

$14

3 years 10 months 24 days ago
(30-Nov-2022)

1/5 (20%)

$-0.13 (-1.28%)

Please subscribe to see extended stock data

Matt Hewitt (CRAIG HALLUM)

Buy Since 11-Aug-2017

$14

$4 (40.00%)

$14

3 years 10 months 25 days ago
(29-Nov-2022)

1/9 (11.11%)

$3.93 (39.03%)

167

Please subscribe to see extended stock data

Chris Cooley (STEPHENS)

Buy Since 09-Sep-2021

$-1 (-10.00%)

$13

4 years 5 months 20 days ago
(04-May-2022)

1/3 (33.33%)

$3.44 (61.87%)

209

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Adam Maeder most bullish on?

Potential upside of $17.71 has been obtained for ISRG (INTUITIVE SURGICAL)

Which stock is Adam Maeder most reserved on?

Potential downside of -$27.86 has been obtained for RMD (RESMED)

What Year was the first public recommendation made by Adam Maeder?

On 2019